Sign In
Buy MBRX
$2.46
+0 (+0%)
At Close: Jun 03, 2026
Moleculin to Report First Quarter Financial Results on May 11, 2023 and Host Conference Call and Webcast
08:35am, Thursday, 04'th May 2023
HOUSTON , May 4, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targetin
Here's Why Moleculin Biotech, Inc. (MBRX) Looks Ripe for Bottom Fishing
11:25am, Monday, 24'th Apr 2023
Moleculin Biotech, Inc. (MBRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreem
Moleculin Biotech, Inc. (MBRX) Upgraded to Buy: What Does It Mean for the Stock?
01:45pm, Monday, 27'th Mar 2023
Moleculin Biotech, Inc. (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Moleculin to Present at the Oppenheimer 33rd Annual Healthcare Conference
08:35am, Monday, 13'th Mar 2023
Presentation with live video webcast on Tuesday, March 14 th at 12:40 PM ET HOUSTON , March 13, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical st
Moleculin to Present at the Virtual Investor 2023 Companies to Watch Event
08:45am, Thursday, 05'th Jan 2023
Live video webcast on Tuesday, January 17 th at 9:00 AM ET HOUSTON, Jan. 5, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceut
Celularity, Moleculin Biotech And 2 Other Penny Stocks Insiders Are Aggressively Buying
11:11am, Tuesday, 29'th Nov 2022 Benzinga
The Dow Jones closed lower by around 500 points on Monday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday
08:49am, Tuesday, 22'nd Nov 2022 Benzinga
Gainers
Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash.
NeuroOne Medical Techn
Moleculin Biotech, Inc. (MBRX) Q3 2022 Earnings Call Transcript
12:57pm, Saturday, 12'th Nov 2022
Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Walter Klemp – Chairman and Chief Executive Officer Jonathan Foster – Exec
HOUSTON , Nov. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti
Moleculin Biotech to Present at the Virtual Investor Innovations in Acute Myeloid Leukemia (AML) Spotlight Event
09:11am, Friday, 23'rd Sep 2022
– Live moderated video webcast with members of management to discuss its ongoing Phase 1/2 study of core technology in development, Annamycin for the treatment of Acute Myeloid Leukemia, on Wednesda
Moleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
08:45am, Thursday, 08'th Sep 2022
HOUSTON , Sept. 8, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targ
Moleculin to Present at the H.C. Wainwright 24th Annual Global Investment Conference
08:35am, Wednesday, 07'th Sep 2022
HOUSTON , Sept. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates ta
Moleculin to Present at the H.C. Wainwright Global Investment Conference
08:05am, Thursday, 19'th May 2022
HOUSTON, May 19, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targ
FDA Clears Moleculin's IND Application To Conduct Phase 1 Study Of WP1066 For Recurrent Malignant Glioma
02:31pm, Thursday, 21'st Apr 2022 Benzinga
Moleculin Biotech, Inc. (NASDAQ: MBRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application of the drug candidate WP1066 for Recurrent
Moleculin to Present at the Oppenheimer 32nd Annual Healthcare Conference
08:05am, Friday, 11'th Mar 2022
HOUSTON, March 11, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targe
